ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Procollagen I N-Peptide are available for Human and Mouse which can be quantified in various samples, including plasma, serum.
Invitrogen ELISA kits exist in two formats:...ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Procollagen I N-Peptide are available for Human and Mouse which can be quantified in various samples, including plasma, serum.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated....ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Procollagen I N-Peptide are available for Human and Mouse which can be quantified in various samples, including plasma, serum.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits include all the necessary reagents to coat your own plates and run your assay with maximum flexibility. Coated ELISA kits...
ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Procollagen I N-Peptide are available for Human and Mouse which can be quantified in various samples, including plasma, serum.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits include all the necessary reagents to coat your own plates and run your assay with maximum flexibility. Coated ELISA kits are ready-to-use and quality tested for sensitivity, specificity, precision and lot-to-lot consistency.
靶标信息
Procollagen type I N-terminal propeptide (P1NP) is a specific marker of bone formation, reflecting the synthesis of type I collagen, which constitutes the major part of the bone matrix. P1NP is derived during the conversion of procollagen to collagen, produced by osteoblasts during bone formation. Its primary clinical application lies in the diagnosis and monitoring of metabolic bone diseases, particularly osteoporosis. In osteoporotic patients, P1NP levels can predict bone mineral density (BMD) responses to treatments like teriparatide and romosozumab. Low serum levels of P1NP are indicative of a high risk of BMD loss, providing a valuable tool for premenopausal women with systemic lupus erythematosus (SLE) and other conditions affecting bone health.